Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 2/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | GALK1 | P51570 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20205894 | 0.86 | RET (0.42) | RETMCHR1CTSASMYD3ACKR3 | |
| SCHEMBL20147628 | 0.82 | RET (0.40) | RETMCHR1CTSASMYD3ACKR3 | |
| SCHEMBL21651990 | 0.77 | RET (0.43) | RETMCHR1ADAM17CCR3OPRM1 | |
| SCHEMBL21651995 | 0.76 | MCHR1 (0.45) | RETMCHR1CTSAADAM17CCR3 | |
| SCHEMBL25504243 | 0.75 | ACKR3 (0.45) | RETMCHR1SMYD3ACKR3 | |
| SCHEMBL21651966 | 0.75 | P2RX7 (0.41) | RETMCHR1ADAM17CCR3OPRM1 | |
| SCHEMBL21652051 | 0.73 | RAD52 (0.46) | RETOPRD1RAD52KMT2A | |
| SCHEMBL25504255 | 0.72 | P2RX7 (0.48) | RETMCHR1SMYD3ACKR3CCR3 | |
| SCHEMBL25504106 | 0.72 | RET (0.45) | RETCCR3 | |
| SCHEMBL25504101 | 0.72 | RET (0.45) | RETMCHR1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | RET 1/4885MCHR1 1063/4885CTSA 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.